BioCentury
ARTICLE | Deals

23andMe’s data find home via Regeneron takeout in bankruptcy: Deals Report

Plus: Biomarin/Inozyme, GSK/Boston Pharma, Abbvie/Adarx, Novo/Septerna and more

May 19, 2025 10:21 PM UTC

After weeks of concern about where 23andMe’s repository of consumer genetic data will land, Regeneron has agreed to buy the company in a bankruptcy court-supervised transaction and maintain its business.

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is pledging to safeguard the dataset from 23andMe Holding Co. (OTC:MEHCQ) with “high standards of data privacy, security and ethical oversight” and preserve the company’s consumer-facing personal genetics business along with its health and research services...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article